Human Multiple Myeloma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated)

Description

Human Multiple Myeloma Peripheral Blood Mononuclear Cells (MM PBMCs) (Newly Diagnosed/Untreated) are derived from the peripheral blood of newly diagnosed and untreated multiple myeloma patients. They are isolated by gradient centrifugation technology (such as Ficoll density gradient method) to obtain a mixed cell population rich in lymphocytes (T cells and B cells, NK cells), monocytes and dendritic cells. Morphologically, the cells are round to oval-shaped, mononuclear, grow in suspension, and show low adherence to plastic surfaces. Clonal B cells exhibit monoclonal immunoglobulin overexpression, while myeloid-derived suppressor cells (MDSCs) demonstrate elevated marker expression. Concurrently, T cell function is suppressed through arginase-1 and indoleamine 2, 3-dioxygenase (IDO)-dependent mechanisms. Functionally, these cells retain immune surveillance and regulatory components, but their activity is dysregulated in the disease state. Clonal B-cell expansion leads to monoclonal immunoglobulin secretion, while myeloid-derived suppressor cells (MDSCs) accumulate disproportionately. At the same time, T-cell function is suppressed via immunosuppressive pathways (e.g., arginase-1 and indoleamine 2, 3-dioxygenase [IDO]), collectively fostering tumor immune escape. In translational research settings, multiple myeloma PBMC samples from newly diagnosed multiple myeloma and untreated multiple myeloma patients are leveraged as peripheral blood mononuclear cells myeloma resources to enable comprehensive multiple myeloma immune profiling and in-depth PBMC analysis multiple myeloma across disease-relevant immune compartments.